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Background: The average age of patients with hepatocellular carcinoma (HCC) has been increasing
worldwide. This study aimed to clarify the aged-speciﬁc clinical characteristics of HCC among elderly
patients.
Materials and methods: We retrospectively analyzed 1123 patients with HCC treated between 2003 and
2006 at the Mackay Memorial Hospital in Taiwan. Patients aged more than 75 years of age at the time of
diagnosis of HCC were deﬁned as the elderly group. According to the KaplaneMeier method, survival
curves were compared between patients receiving treatment and those receiving supportive care.
Results: A total of 169 patients (16.9%) were included in the elderly group. The mean age of the patients at
the time of diagnosis was 80  3.6 years. The sex ratio (male to female) was 1:0.72. The proportion of
patients positive for hepatitis C virus antibody (HCVAb) and hepatitis B surface antigen (HBsAg) were
49.1% and 19.5%, respectively. The percentages of patients in the Cancer of the Liver Italian Program
(CLIP) score categories 0e1, 2e3, and 4e6 were 44%, 39%, and 17 %, respectively. Of the 169 patients, 114
patients (67.5%) underwent treatmentdtranscatheter arterial embolization (TAE, n ¼ 52, 45.7%), being
the predominant treatment methoddwhile 55 patients (32.5%) received supportive care. There cumu-
lative survival curves of the treated group and the supportive care group differed signiﬁcantly for HCC
patients in the CLIP score categories 0e1 (p < 0.001) and 2e3 (p ¼ 0.021), while there was no difference
in these survival curves for HCC patients in the CLIP score category 4e6.
Conclusion: Most elderly patients at the time of diagnosis of HCC were in CLIP score category 0e1.
Transcatheter arterial embolization was the predominant treatment method at our hospital. Aggressive
treatment for HCC, especially in CLIP score category 0e3, might improve the survival rate.
Copyright  2013, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC), one of the most common
cancers worldwide, is increasing in frequency among Asian and
Western countries1. Owing to the high prevalence of endemic
hepatitis B virus (HBV), the majority of HCC cases occur in devel-
oping countries, particularly in Asia. Recently, due to the sequel of
hepatitis C virus (HCV) and alcoholic cirrhosis, there has been
increasing numbers of HCC cases in Western countries2. The risk of
developing HCC is known to be age dependent3; therefore, we areerest.
vision of Gastroenterology,
Hospital, Number 92, Section
Chang).
iwan Society of Geriatric Emergenlikely to see an increased number of elderly patients diagnosed
with HCC in the coming years owing to the general increase in the
population longevity. In comparison to the younger age patients,
the elderly group shows signiﬁcantly higher comorbidity, particu-
larly with pulmonary and cardiovascular diseases. Furthermore, the
therapeutic advantage of cancer treatment among elderly patients
is largely unknown, as they have generally been underrepresented
in clinical trials3. Owing to the fact that treatment is oftenwithheld
from them for the fear of potential toxicities or perceived minimal
survival beneﬁt, many elderly patients do not receive optimal
cancer treatment3. Hence, clinical characteristics and the long-term
prognosis of these patients still remain obscure.
“Elderly patients” usually refers to those in the ages of 60 years,
65 years, or 70 years and above4e6. Furthermore, with an increase
in the average lifespan, the age at which a person is considered
elderly is also rising. Hence, clarifying the optimal treatment
strategy for elderly patients with HCC has become an urgentcy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Age distribution of patients with hepatocellular carcinoma
(HCC).
Age (y) Number of HCC patients
<35 45
36-45 99
46-55 217
56-65 267
66-75 314
76-85 161
>86 20
Total 1123
Table 2
Proﬁle of elderly patients with hepatocellular carcinoma.
Elderly (age > 75 y)
Sex (male/female) 98/71
Mean age (range) 80  3.6 (76e92)
HBsAg/Anti-HCV/NBNC/uk 33/83/43/11
Child-Pugh grading (A/B/C) 72/59/17
Stage (I/II/IIIA/IIIB/IIIC/IV/uk) 66/34/51/1/5/10/2
Okuda (I/II/III/uk) 56/84/28/1
CLIP score
0e1 75
2e3 66
4e6 28
Portal thrombosis (e/þ) 134/31
Ascites (e/þ) 116/52
Total bilirubin (mg/dL) 1.77  2.51
Albumin (g/dL) 3.06  0.66
PT (INR) 1.13  0.28
AFP (ng/mL)
<200 76
200e400 14
>400 61
AFP ¼ alpha-fetoprotein; CLIP ¼ Cancer of the Liver Italian Program;
HBsAg ¼ hepatitis B surface antigen; Anti-HCV ¼ antibodies against hepatitis C;
NBNC ¼ non-B non-C hepatitis; uk ¼ unknown.
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evaluating elderly patients with HCC4e6. Therefore, this study aims
to clarify the age-speciﬁc clinical characteristics of HCC and eval-
uate the survival rates and characteristics among elderly HCC pa-
tients. Therefore, we undertook a retrospective study of elderly HCC
patients over 75 years of age receiving aggressive treatment in
comparison to elderly HCC patients receiving supportive care.
2. Materials and methods
A total of 1123 patients diagnosed with HCC presented to the
Mackay Memorial Hospital between January 2003 and December
2006. The diagnosis of HCC was conﬁrmed either by histology or
cytology, elevated serum alpha-fetoprotein (AFP) level (>400 ng/
mL), or imaging evidence of tumor formation in the liver (with
arterial hypervascularization) on dynamic imaging modalities
[computed tomography (CT)7, magnetic resonance imaging (MRI),
and angiography]. Patients with more than 75 years of age at the
time of diagnosis of HCC were deﬁned as the elderly group.
For each patient, the following data were recorded: age, sex,
hepatitis B surface antigen (HBsAg), hepatitis C virus antibody
(HCVAb), biochemical analysis (total bilirubin, albumin, pro-
thrombin time, and platelet count), serum AFP, diameter and
number of tumors, Child-Pugh grading, tumor staging, presence of
portal thrombosis or ascites, initial therapy, and survival. The
presence of concomitant disease with a strong impact on the
prognosis (e.g., malignant neoplasm, cardiovascular disease, and
cerebrovascular disease) was recorded. The types of initial treat-
ment for HCC were divided into six categories: (1) transcatheter
arterial embolization (TAE); (2) percutaneous ethanol injection
treatment (PEIT) or radiofrequency ablation (RFA); (3) surgical
resection, including liver transplantation; (4) systemic or reservoir
chemotherapy; (5) radiotherapy; and (6) supportive care. Accord-
ing to the KaplaneMeier method, the survival curves were
compared between patients receiving aggressive treatment and
supportive care. Cancer stage was scored according to the latest
version of the Cancer of the Liver Italian Program (CLIP), Okuda
classiﬁcation and the TNM classiﬁcation of malignant tumors
system7,8. The CLIP score categories were grouped as 0e1, 2e3, and
4e6 for statistical analysis because of the low number of patients
within such categories. The Barcelona Clinic Liver Cancer (BCLC)
staging system was not used as many cases lacked information on
performance status.
2.1. Statistical analyses
The data are expressed as mean  standard deviation (SD).
Statistical analyses were carried out using Student t test for
unpaired data, Chi-square (c2) test, or Fisher’s exact test as
appropriate. The cumulative survival curves according to
the KaplaneMeier method were compared using the log-rank test.
A p value of <0.05 was considered statistically signiﬁcant. All sta-
tistical analyses were performed using the SPSS version 13.0 (SPSS
Inc., Chicago, IL, USA).
3. Results
A total of 1123 consecutive patients were enrolled in this study.
The age distribution of patients with HCC is shown in Table 1. The
mean age of the 1123 patients with HCC was 61.7  14.0 years
(range: 2e92 years; median: 63 years). A total of 181 patients
(16.1%) were older than 75 years.
A total of 169 elderly patients were included in this study. The
demographic and characteristics of the elderly group are summa-
rized in Table 2. The mean age of the patients at the time ofdiagnosis was 80  3.6 years (range: 76e92 years). Elderly patients
were more likely to be male and infected by HCV, whereas HBV
infection was less common; the sex ratio (male to female) was
1:0.72 and the proportion of patients positive for HCVAb and HBsAg
were 49.1% and 19.5%, respectively. Most patients (42.6%) were in
the Child-Pugh stage A category, whereas Child-Pugh stage C
(10.1%) was least represented. Okuda stage II category was the most
frequent (49.7%). Sixty-one patients (36.1%) had elevated serum
AFP level > 400 ng/mL. Portal vein thrombosis, either partial
or complete, was detected in 18.3% of patients. CLIP score category
0e1 was the most frequent group (44.4%), whereas CLIP score
category 4e6 (16.6%) was least represented.
Table 3 shows the initial treatment modalities for these elderly
patients. A total of 114 patients underwent aggressive treatment.
CLIP score category 0e1 (n ¼ 57, 50%) was the most frequent group.
Most of the these 114 patients received TAE; the percentage of
patients who received TAE, PEIT, or RFA, surgery, medicine, and
radiotherapy were 45.6%, 20.2%, 14.0%, 11.4%, and 8.8%, respectively.
A total of 55 patients received supportive care and CLIP score
category 2e3 (n ¼ 22, 40%) was the most frequent group.
Fig. 1A shows signiﬁcant differences in cumulative survival
curves between the aggressive treatment group and supportive
treatment group (p < 0.001). There were also signiﬁcant difference
in cumulative survival curves of the treated group and supportive
care group in CLIP score category 0e1 (Fig. 1B, p < 0.001) and CLIP
score category 2-3 (Fig. 1C, p ¼ 0.021). There were no difference in
Table 3
Type of initial treatment for elderly patients with hepatocellular carcinoma in
different Cancer of the Liver Italian Program (CLIP) score.
Treatment n CLIP 0e1 CLIP 2e3 CLIP 4e6
Aggressive treatment 114 57 44 13
TAE 52 25 26 1
PEI or RFA 23 15 5 3
Surgery 16 14 2 0
Medicine 13 1 6 6
Radiotherapy 10 2 5 3
Supportive care 55 18 22 15
PEI ¼ percutaneous ethanol injection; RFA ¼ radiofrequency ablation;
TAE ¼ transcatheter arterial embolization.
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ive care groups in CLIP score category 4e6 (Fig. 1D, p ¼ 0.054).
4. Discussion
The incidence of HCC has a marked geographical variability,
particularly high in South-East Asia and southern Africa, and lower
in North America and northern Europe9. However, recent studiesFig. 1. Survival curves of aggressive treatment and supportive care for elderly patient with h
(D) 4e6. p < 0.05 was considered statistically signiﬁcant.have shown a rising incidence over the past decades in low-risk
areas9,10. Similarly, the peak age of HCC occurrence varies consid-
erably worldwide owing to the differences in the distribution of its
three main etiological factors, namely, HBV and C virus HCV in-
fections and alcohol abuse. Each of these factors have different age
peaks of exposure and dissimilar intrinsic mutagenic properties
requiring different times for the neoplastic transformation of the
liver11. Speciﬁcally, in developed countries, where HCV and alcohol
account for most HCCs, the median age of patients is over 60
years12. Moreover, the number of elderly patients diagnosed with
HCC is expected to increase in most developed areas owing to the
following epidemiological phenomena. First, the decreasing inci-
dence of HBV infection, which is frequently acquired in the ﬁrst two
decades of life13. Second, the “delaying” effect of antiviral therapy
on the occurrence of HCC in HBV and HCV infected cases14. Third,
the rising incidence of “cryptogenic” and nonalcoholic steatohe-
patitis (NASH)- related cirrhosis, having a long-lasting and insid-
ious development15.
Our study showed that elderly patients were more likely to be
infected by HCV, whereas HBV infection was less common. The
incidence of HCV-related HCC has also increased in recent years16.
Two large studies showed that the mean ages of their HBV- andepatocellular carcinoma in (A) all patients, CLIP score categories (B) 0e1, (C) 2e3, and
T.-E. Wang et al.88HCV-related HCC patients were 53e55 years and 65 years16,17,
respectively, i.e., the mean age of HBV-related HCC patients was
about 10 years younger than that of the HCV-related HCC pa-
tients16. Another study from the USA showed that the median age
of HCC patients at diagnosis was 74 years, and most patients (91%)
were over 65 years of age18. Prolonged health adjusted life expec-
tancy (HALE) can be predicted at birth; for 2000 and 2006, HALE at
birth was 79.56 years and 80.81 years for Taiwanese females,
respectively, and 73.83 years and 74.57 years for Taiwanese males,
respectively19. Thus, the incidence rate of HCC signiﬁcantly
increased with advancing age owing to prolonged HALE. In Taiwan,
the signiﬁcant increases in the risk of HCV-related HCC incidence is
also associated with increasing age20.
In most reported series of HCC, the male-to-female ratio range
from 2:1 to 8:121,22. The tumors in women tend to have less
aggressive characteristics than in men, such as smaller mean tumor
size, less advanced Okuda stage, and less frequent portal or hepatic
vein invasion22. Although the exact reasons for the unequal gender
distribution is unclear, investigators have postulated that differ-
ences in deoxyribonucleic acid (DNA) synthetic activity and sex
hormones may contribute to it at least in part23. Studies from ani-
mal models suggest that the hormonal effect may be related to
testosterone’s ability to enhance transforming growth factor alpha-
related hepatocarcinogenesis and hepatocyte proliferation24.
Additionally, men may also have a higher incidence of HBV infec-
tion and cirrhosis as well as lifestyle differences (such as heavy
alcohol consumption and smoking) that contribute to their
increased risk25,26.
We found that aggressive treatment for HCC, especially in the
CLIP score category 0e3, improved the survival rate. The ﬁrst line of
treatment for patients with HCC is surgical resection, liver trans-
plantation, RFA, or PEIT27. There may be several reasons to explain
the undertreatment of elderly patients. Firstly, an attitude toward
the undertreatment of hepatocellular carcinoma has been widely
disseminated because of the coexistence of liver cirrhosis in most
patients, preventing more aggressive treatment approaches. This is
one of the reasons why most staging and prognostic systems for
hepatocellular carcinoma include the assessment of liver function
as well as tumor extension8. Furthermore, owing to the accumu-
lation of different diseases, it is possible that elderly patients might
not be able to tolerate the debilitating effects of radical surgery and
locoregional treatment. However, some recent retrospective data
showed that surgical resection, percutaneous ethanol injection, and
transarterial chemoembolization can be performed safely in elderly
cirrhotic patients4,28e30. In recent retrospective reports, both Hir-
aoka et al31 and Takahashi et al32 showed that elderly patients can
also be safely treated by radiofrequency ablationwith survival rates
comparable to those of their younger group. We also found
the aggressive treatment for HCC patients in group of CLIP category
4e6, more advanced HCC patients, did not improve the survival
rate. Although the difference did not reach statistical signiﬁcance in
this small subgroup, the HCC patients who received supportive care
seemed to show a trend of better survival rate than those under-
going treatment. These ﬁndings refer to small series and thus must
be conﬁrmed prospectively.
The key issue in our study is whether the outcome of HCC
treatments is affected by age. In fact, even for this topic, there is no
agreement because the outcome was found to be either age-inde-
pendent4,29 or adversely affected by ageing33,34. The latter evi-
dence, however, could be biased by the “undertreatment” of older
individuals. Despite the liver function and cancer stage that were
no worse than in younger individuals, a conservative approach was
chosen for most elderly patients. A recent study involving the
retrospective analysis of a large patient cohort provides compelling
evidence that age does not affect the outcome of HCC treatments35.In conclusion, although there was a lack of strong evidence
regarding treatment efﬁcacy, our data suggest that some methods
of treatment should not be denied to elderly patients only on the
basis of chronological age. To improve physicians’ attitude toward
treatment of elderly patients, proper clinical trials dedicated to this
subgroup should be planned.References
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